Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2012-02-01

Summary

The purpose of this study is to determine whether a combination of the drugs docetaxel (Taxotere ® ), plus vinorelbine (Navelbine ® ), will result in fewer side effects than cisplatin chemotherapy, thereby improving delivery of chemotherapy in patients.

Another purpose of this study is to determine whether a third drug, bevacizumab (Avastin®), may be delivered safely with docetaxel plus vinorelbine in patients who are eligible to receive bevacizumab.

• Phase: N/A

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Sanofi
• Treatments: Bevacizumab; Docetaxel; Vinblastine; Vinorelbine